Do you know DIC? Disseminated intravascular coagulation explained

Disseminated intravascular coagulation (or DIC) is an acute condition wherein coagulation happens... wait for it... intravascularly... in a disseminated fashion. But what does this actually mean for the patient? Why does it happen? When does it happen? What can be done about it? And what testing can we do to understand the patient's condition?

Coagulation: Platelets + Fibrin clot

The best place to start is at normal coagulation. Under normal physiologic conditions, coagulation is tightly localized to sites of vascular injury. Platelets adhere to damaged endothelium, coagulation factors become sequentially activated, fibrin forms, and a stable clot develops precisely where it is needed.

In DIC, however, this process escapes local control. Coagulation becomes systemically activated throughout the vasculature, resulting in diffuse fibrin deposition and widespread microthrombi formation. Ironically, while the patient is clotting excessively in some areas, they are simultaneously consuming the very platelets and coagulation factors necessary to maintain normal hemostasis elsewhere. The result is a paradoxical state in which thrombosis and hemorrhage occur concurrently.

The pathophysiology of DIC is fundamentally driven by overwhelming activation of the coagulation cascade, most commonly through tissue factor exposure and inflammatory cytokine signaling. Remember, tissue factor is the factor that kicks off the EXTRINSIC pathway. In severe systemic illness, massive tissue factor release can occur from damaged endothelial cells, monocytes, or injured tissues. This generates excessive thrombin production, converting fibrinogen into fibrin on a widespread scale. Simultaneously, physiologic anticoagulant systems—including antithrombin, protein C, and tissue factor pathway inhibitor—become depleted or impaired. Fibrinolytic systems may initially activate in an attempt to dissolve clots, but they are often overwhelmed or dysregulated as the condition progresses.

Ok, so if tissue factor starts all of this, what conditions would cause a massive release of tissue factor?

Sepsis is among the most common precipitants, particularly gram-negative bacterial infections that produce potent inflammatory responses.

Severe physical trauma, extensive burns, and major transfusion reactions are also classic causes.

In obstetrics, placental abruption, amniotic fluid embolism, retained fetal demise, and severe preeclampsia can all trigger explosive coagulation activation.

Certain malignancies, especially acute promyelocytic leukemia and mucin-producing adenocarcinomas, are strongly associated with chronic or acute DIC syndromes.

Petechiae on the mucosae of the patient. Classic DIC.

Diagnosis

The manifestations of DIC vary according to the balance between thrombosis and bleeding. In some patients, diffuse microvascular thrombosis predominates. Small fibrin-rich clots form within capillaries and arterioles, impairing tissue perfusion and causing ischemic injury. Organ dysfunction may develop rapidly, affecting the kidneys, lungs, liver, brain, and adrenal glands. Renal failure, respiratory distress, altered mental status, and shock may all emerge as downstream consequences of microvascular occlusion.

In other patients, bleeding manifestations are more clinically apparent. Because platelets and clotting factors are continuously consumed, the patient develops a consumptive coagulopathy. Oozing may occur from venipuncture sites, surgical wounds, mucosal surfaces, or indwelling catheters. Petechiae and ecchymoses may develop across the skin. Gastrointestinal bleeding, hematuria, pulmonary hemorrhage, and intracranial hemorrhage can occur in severe cases. Importantly, the presence of bleeding does not mean the patient is not clotting; rather, it reflects exhaustion of coagulation factors after widespread intravascular coagulation has already occurred.

Laboratory Evaluation

PT (prothrombin time) is typically prolonged in DIC. This occurs because factors involved in the extrinsic and common pathways—particularly factors I (fibrinogen), II (prothrombin), V, VII, and X—are consumed during widespread clot formation. Since factor VII has a relatively short half-life, PT often becomes abnormal early in the disease course.

aPTT (activated partial thromboplastin time) is also commonly prolonged. Consumption of intrinsic pathway factors such as VIII, IX, XI, and XII contributes to delayed clot formation in the assay. However, early DIC can occasionally show a normal or even shortened aPTT because acute inflammatory states may transiently elevate factor VIII levels before consumption becomes dominant.

Fibrinogen levels are generally decreased. In DIC, fibrinogen is rapidly converted into fibrin as thrombin generation accelerates throughout the vasculature. Severe acute DIC can produce profound hypofibrinogenemia. However, interpretation requires caution because fibrinogen is also an acute phase reactant; in inflammatory states such as sepsis, fibrinogen production may initially rise, masking early consumption.

D-dimer levels are markedly elevated and are among the most sensitive indicators of DIC. D-dimer is generated when plasmin degrades cross-linked fibrin. Because DIC involves massive fibrin formation followed by fibrinolysis, D-dimer concentrations often become dramatically increased. Elevated fibrin degradation products (FDPs) accompany this process.

Thrombin time (TT) is usually prolonged as well. The thrombin time specifically evaluates the conversion of fibrinogen into fibrin after addition of exogenous thrombin. In DIC, low fibrinogen levels and circulating fibrin degradation products interfere with fibrin polymerization, causing delayed clot formation during the assay.

Properly filled and centrifuged citrate tubes!

Treatment

Management of DIC primarily centers upon treatment of the underlying cause. Without controlling the precipitating insult, supportive therapy alone is rarely sufficient. In septic patients, rapid antimicrobial therapy and source control are essential. Obstetric causes may require emergent delivery or surgical intervention. Malignancy-associated DIC improves only when the underlying cancer is appropriately treated.

Supportive management focuses on stabilization of coagulation function and mitigation of bleeding or thrombotic complications. Patients with significant bleeding or those requiring invasive procedures may need transfusion support. Platelet transfusions can help restore primary hemostasis in severely thrombocytopenic patients. Fresh frozen plasma replenishes depleted coagulation factors, while cryoprecipitate or fibrinogen concentrate may be used to correct severe hypofibrinogenemia.

Interestingly, anticoagulation may occasionally be indicated despite the bleeding risk. In patients where thrombosis predominates—particularly those with chronic DIC associated with malignancy—heparin therapy can reduce ongoing coagulation activation. However, anticoagulation decisions require careful clinical judgment and depend heavily upon the patient’s bleeding status and overall presentation.